X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Aurobindo Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs AUROBINDO PHARMA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA AUROBINDO PHARMA TORRENT PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 25.9 18.0 143.8% View Chart
P/BV x 6.3 5.8 108.4% View Chart
Dividend Yield % 3.2 0.4 889.1%  

Financials

 TORRENT PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
AUROBINDO PHARMA
Mar-16
TORRENT PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,7201,541 111.6%   
Low Rs1,134582 194.8%   
Sales per share (Unadj.) Rs394.5237.5 166.1%  
Earnings per share (Unadj.) Rs101.833.9 300.5%  
Cash flow per share (Unadj.) Rs116.340.6 286.7%  
Dividends per share (Unadj.) Rs40.002.50 1,600.0%  
Dividend yield (eoy) %2.80.2 1,190.2%  
Book value per share (Unadj.) Rs200.3120.6 166.1%  
Shares outstanding (eoy) m169.22585.17 28.9%   
Bonus/Rights/Conversions -PREF-  
Price / Sales ratio x3.64.5 80.9%   
Avg P/E ratio x14.031.3 44.7%  
P/CF ratio (eoy) x12.326.2 46.9%  
Price / Book Value ratio x7.18.8 80.9%  
Dividend payout %39.37.4 532.4%   
Avg Mkt Cap Rs m241,435621,041 38.9%   
No. of employees `00010.913.3 82.0%   
Total wages/salary Rs m8,55915,508 55.2%   
Avg. sales/employee Rs Th6,129.610,457.6 58.6%   
Avg. wages/employee Rs Th785.81,167.1 67.3%   
Avg. net profit/employee Rs Th1,581.31,491.6 106.0%   
INCOME DATA
Net Sales Rs m66,764138,961 48.0%  
Other income Rs m2,1561,663 129.7%   
Total revenues Rs m68,920140,624 49.0%   
Gross profit Rs m27,20432,056 84.9%  
Depreciation Rs m2,4613,926 62.7%   
Interest Rs m1,8592,568 72.4%   
Profit before tax Rs m25,04127,225 92.0%   
Minority Interest Rs m039 -0.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,4147,444 86.2%   
Profit after tax Rs m17,22419,820 86.9%  
Gross profit margin %40.723.1 176.6%  
Effective tax rate %25.627.3 93.7%   
Net profit margin %25.814.3 180.9%  
BALANCE SHEET DATA
Current assets Rs m46,622100,015 46.6%   
Current liabilities Rs m32,84374,759 43.9%   
Net working cap to sales %20.618.2 113.6%  
Current ratio x1.41.3 106.1%  
Inventory Days Days74107 69.1%  
Debtors Days Days79110 72.1%  
Net fixed assets Rs m39,02952,350 74.6%   
Share capital Rs m846585 144.6%   
"Free" reserves Rs m31,40067,707 46.4%   
Net worth Rs m33,89070,567 48.0%   
Long term debt Rs m18,6378,472 220.0%   
Total assets Rs m90,136156,994 57.4%  
Interest coverage x14.511.6 124.7%   
Debt to equity ratio x0.50.1 458.1%  
Sales to assets ratio x0.70.9 83.7%   
Return on assets %21.214.3 148.5%  
Return on equity %50.828.1 180.9%  
Return on capital %48.537.7 128.6%  
Exports to sales %43.351.0 84.9%   
Imports to sales %6.918.8 36.4%   
Exports (fob) Rs m28,93470,927 40.8%   
Imports (cif) Rs m4,58426,193 17.5%   
Fx inflow Rs m29,18571,015 41.1%   
Fx outflow Rs m6,02128,799 20.9%   
Net fx Rs m23,16542,216 54.9%   
CASH FLOW
From Operations Rs m27,13217,596 154.2%  
From Investments Rs m-7,014-13,801 50.8%  
From Financial Activity Rs m-14,352-198 7,237.3%  
Net Cashflow Rs m5,7673,597 160.3%  

Share Holding

Indian Promoters % 71.5 54.1 132.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 8.0 88.3%  
FIIs % 12.6 27.7 45.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.2 86.3%  
Shareholders   26,511 69,601 38.1%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS